Treatment for AML children may rely on downstream effectors of receptor tyrosine kinase (RTK), such as the Ras and phospholipase D signaling pathways [54], since we discovered NRAS, KIT, PTPN11 and KRAS in the two pathways when comparing AML_TARGET (children) to LAML (adults), LAML_CN (adults) and LAML_KR (adults) at K = 4 (Fig 4A left C/A and Table S3.7 in S1 Data). This evidence concerns the gene KRAS and acute myeloid leukemia.